Introduction
============

Over the past two decades, significant evidence has suggested a close relation between pathophysiology of Heart failure (HF) and increased oxidative stress, both systemically and in pericardial fluid [@B1],[@B2]. Oxidative stress describes an imbalance between antioxidant defences and the production of reactive oxygen species (ROS), which at high levels cause cell damage but at lower levels induce subtle changes in intracellular signalling pathways [@B3]. Increased oxidative stress is implicated in most types of HF, including that resulting from ischaemic and non‐ischaemic cardiomyopathy, pressure and volume overload, tachycardiomyopathy and chemotherapy‐induced failure [@B3]. The adverse effects of oxidative stress in HF patients are vascular endothelial dysfunction [@B4], cardiac hypertrophy [@B5], interstitial fibrosis [@B6], myocyte contractile dysfunction [@B7] and adverse left ventricular remodelling after myocardial infarction [@B2].

Heart failure (HF) is a growing epidemic with the annual number of hospitalizations constantly increasing over the last decades for HF as a primary or secondary diagnosis [@B8]. To address the need to support the circulation in patients with end-stage HF a wide variety of mechanical circulatory support devices have been developed over the past four decades. Left ventricular assist devices (LVAD) therapy has evolved into a standard therapy for patients with advanced HF [@B9],[@B10],[@B11], not only as a bridge to cardiac transplantation but also as a destination therapy or a bridge to myocardial recovery [@B12],[@B13]. This increase is attributed to the success of new second-generation continuous-flow devices [@B14], although a substantial portion of patients suffer from numerous co-morbidities [@B15].

Oxidative stress specifically activated by diverse stimuli that are important in cardiovascular pathology---for example, angiotensin II, endothelin 1, cytokines, growth factors, oxidised low density lipoproteins (oxLDL), mechanical stretch and even high shear stress [@B16],[@B17]. Recently, Caruso et al., 2012 showed that the levels of oxidative-inflammatory markers were higher in LVAD recipients compared to other groups [@B18]. Previous investigation indicated that oxidative stress may promote the development of multiple organ failure in patients suffering from systemic inflammatory disease [@B19]. Moreover, LVAD is responsible for inflammatory cytokine production in HF patients and other research investigations reported that cytokine stimulation is positively associated with oxidative stress [@B20],[@B21],[@B22]. Oxidative stress is also responsible for damage to DNA, membranes, proteins and other macromolecules. Previous study reported that somatic DNA damage contribute to the pathogenesis of atherosclerosis and elevated levels of oxidative DNA damage in HF patients [@B23]. Moreover, biomarkers of oxidative DNA damage was significantly higher in HF patients and the severity of damage was positively associated with end stage HF (NYHA class IV) [@B24].

The pathophysiological effects of ROS depend on the type, concentration and specific site of production. When the local levels of ROS are high, they tend to react with numerous protein centres, DNA, cell membranes and other molecules, causing considerable cellular damage as well as generating other more reactive radicals. In HF patients supported by LVADs, circulating blood is continuously experiencing non-physiological elevated shear stresses and in direct contact with the biomaterials of LVADs. Previous studies showed that high shear stress is responsible for ROS generation [@B25] and DNA damage [@B26]. So it is reasonable to assume that long-term exposure to high shear stress flow environment as well as artificial blood contacting materials in continuous flow LVADs may have an additive role in the excess production of ROS form circulating leukocytes and concomitant DNA damage in lymphocytes. However, till now there is no such report regarding oxidative stress and DNA damage in lymphocytes and the ability of repair these damage in HF patients supported by LVADs. In view of this, the present study has been conducted.

Materials and Methods
=====================

Subjects
--------

We studied 10 HF patients with NYHA class IV undergoing continuous flow LVAD (5 HeartMate II and 5 Jarvik 2000) implantation as bridge to transplant or destination therapy and 10 apparently healthy age and sex matched volunteers as controls. The inclusion criteria for the selection of HF patients were (i) aged between 18 to 70 years, (ii) undergoing contentious flow LVAD implantation and (iii) able to provide informed consent for the study. The inclusion criteria for the age and sex matched control subjects were (i) no clinical evidence of HF or other cardiovascular diseases, (ii) history of malignancy and (iii) inflammatory disease on careful examination and routine laboratory tests. Pregnant or breastfeeding women or women using oral contraceptives were also excluded from the study. History of tobacco use, alcoholism, diabetes and hypertension were common in HF patients in this study. The control subjects were also matched for these conditions. All procedures involving collection of human blood were approved by the Institutional Review Board (IRB). All patients and volunteers gave their written informed consent and were informed about the aims of the study in accordance with the Declaration of Helsinki.

Reagents and chemicals
----------------------

A complete detail of reagents and chemicals including antibodies and kits used in this study can be found in *[Supplementary Material](#SM1){ref-type="supplementary-material"}* under Annexure I.

Collection of blood sample
--------------------------

EDTA-anticoagulated blood samples of the HF patients were collected before LVAD implant surgery (baseline/pre-operative: Pre-OP) and at day 7 (Post-operative duration 1 week: POD-1W), one month (POD-1M), two months (POD-2M) and three months (POD-3M) after the implant surgery. The samples were aliquoted and processed immediately according to the study protocol. Details of sample preparation can be found in *[Supplementary Material](#SM1){ref-type="supplementary-material"}*.

Analysis of oxidative stress and antioxidant defense
----------------------------------------------------

For the analysis of oxidative stress, reactive oxygen species (ROS) in blood leukocytes and superoxide dismutase (SOD) in erythrocytes were measured by flow cytometry [@B27], [@B28] / immunofluorescence microscopy and spectrophotometry, respectively. ELISA was used to measure oxidized low density lipoproteins (*ox*LDL) in plasma. Detailed experimental procedures can be found in *[Supplementary Material](#SM1){ref-type="supplementary-material"}* under Annexure II.

Isolation of blood lymphocytes and immunofluorescence (IF) microscopy
---------------------------------------------------------------------

Detail procedures of lymphocyte isolation and IF microscopy for the assessment of markers of DNA damage (γ-H2AX) and repairs (Mre11, DNA ligase IV, Ku70, and Ku80) proteins can be found in *[Supplementary Material](#SM1){ref-type="supplementary-material"}* under Annexure III.

Statistical analysis
--------------------

The results are presented as mean ± SD (standard deviation) or median with range and statistically analyzed using SPSS statistical software (Statistical Package for Social Sciences for windows, release 10.0; SPSS Inc., Chicago, IL, USA). Statistical differences were determined by using Chi-square test, Student\'s t-test, Mann-Whitney *U* test and One-Way ANOVA post hoc range tests after Bonferroni correction, as applicable. Univariate analysis was carried out using Spearman\'s rank correlation test to find out the relation between two measurable parameters as continuous variables, and the result was expressed as ρ (rho) value. Statistical significance was assigned at P \< 0.05.

Results
=======

Demography and clinical characteristics
---------------------------------------

Demographic and clinical characteristics of HF patients and control subjects are summarized in Table [1](#T1){ref-type="table"}. HF and healthy controls were comparable with respect to age, sex, height, weight, body mass index (BMI) and body surface area. Moreover, history of smoking, alcoholism, diabetes and hypertension were also matched in both groups to exclude the effects of these conditions on the study. All of the HF patients were under NYHA class IV and etiologies of heart disease were either ischemic or non-ischemic cardiomyopathy. The last echocardiographic parameters before LVAD implantation were used for estimation of left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF). The HF patients were implanted with two types of LVADs, the HeartMate II LVAD and the Jarvik 2000 heart, both of which incorporate axial-flow and rotary pump technology and represent the next generation of devices.

We found Warfarin as main anticoagulant drug used by 50% HF patients. Non-steroid anti-inflammatory drug (aspirin \@81 mg daily) and Cardiac glycoside (digoxin @ 125 µg daily) were documented in 40% cases. Use of Beta blocker (carvedilol @ 3.125 - 12.5 mg daily), statin (atorvastatin @ 10 - 40 mg daily) and ACE inhibitor (lisinopril @ 5 - 40 mg daily) were also noted in 70%, 50% and 30% HF patients respectively (Table [1](#T1){ref-type="table"}).

Laboratory Hematology and Blood Chemistry
-----------------------------------------

The comparison of routine laboratory hematology and blood chemistry between the healthy controls and HF patients before and after LVAD implantation during the entire follow up period is summarized in Table [2](#T2){ref-type="table"}. All the hematological and blood chemistry parameters remained within the normal range in the healthy control group while the HF patients had lower levels of hemoglobin, hematocrit and higher levels of blood urea nitrogen (BUN), creatinine and bilirubin (both total and direct) with respect to the normal range before LVAD implantation. Blood Leukocytes, erythrocytes, platelets, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of the HF patients remained within normal range but higher than those of the control group. All the differences in these tests between the HF patients and healthy controls were statistically significant (p\<0.05) except leukocyte count (Table [2](#T2){ref-type="table"}). The HF patients supported with LVAD had significantly higher leukocyte count after one month of LVAD implantation (POD-1M) but returned almost to Pre-LVAD level at month 3 (POD-3M). Erythrocytes, hemoglobin and hematocrit values were decreased through the follow up study and remained below the normal range. Platelet count was reduced to 26% (130 ± 95.05 vs. 175.5 ± 75.75 ×10^3^/µL in Pre-OP, p = 0.3076) at POD-1W of LVAD implantation but returned to the normal range at POD-1M and thereafter. BUN and creatinine levels became the highest at POD-1M but almost returned to Pre-OP levels at the end of study. Levels of total and direct bilirubin slightly increased at POD-1W of LVAD implantation but decreased at each post-operative month and returned to the normal range. AST and ALT values remained within the normal range throughout the study. However 42% (29±8.6 vs. 50.3±15.2 U/L in pre-operative, p =0.0039) reduction in AST value and 41% reduction in ALT value (28.5±15.35 vs. 48.5±14.15 U/L in pre-operative, p = 0.0169) were noted at POD-3M in comparison to pre-operative values (Table [2](#T2){ref-type="table"}).

Oxidative stress: ROS, SOD and oxLDL
------------------------------------

Flow cytometric analysis showed higher MFI of DCF-DA among the HF patients when compared to the healthy controls, suggesting increased ROS generation in peripheral blood leukocytes (Figure [1](#F1){ref-type="fig"}A-[1](#F1){ref-type="fig"}C). The MFI of DCF-DA was 51 % (678.1 ± 131.4 vs. 448.4 ± 105.2), 37 % (492.7 ± 121.2 vs. 358.6 ± 111.5), and 54 % (301.6 ± 102.3 vs. 195.8 ± 76.4) higher in peripheral blood neutrophils, lymphocytes and monocytes respectively at POD-1W of LVAD implantation when compared to the Pre-OP values. During the follow-up measurements up to 3 month after LVAD placement, the MFI of DCF-DA was significantly increased at each post-operative month and became the highest at POD-3M (Figure [1](#F1){ref-type="fig"}A-[1](#F1){ref-type="fig"}C). Microscopic evaluation of intracellular ROS generation in blood leukocytes was in general agreement with the flow cytometric evaluation. The intensity of ROS positive cytoplasm of neutrophils, lymphocytes and monocytes increased with time after LVAD implantation (Figure [2](#F2){ref-type="fig"}).

A significantly lower SOD level in erythrocytes was noted in HF patients than in the healthy controls (Figure [1](#F1){ref-type="fig"}D). Interestingly, SOD levels progressively decreased 27% (144.3 ± 38.4 vs. 197.5 ± 47.6 U/mL), 33% (132.7 ± 24.5 vs. 197.5 ± 47.6 U/mL), 38% (121.5 ± 35.3 vs. 197.5 ± 47.6 U/mL) and 50% (97.8 ± 21.3 vs. 197.5 ± 47.6 U/mL) at POD-1W, POD-1M, POD-2M and POD-3M respectively in compared to the Pre-OP level (Figure [1](#F1){ref-type="fig"}D).

The study also revealed that excessive levels of plasma oxLDL, another important biomarker of oxidative stress, in the HF patients compared to the healthy control. During 3 month post-operative follow up, more than 2-fold increase in the oxLDL level was noted (Figure [1](#F1){ref-type="fig"}E). Spearman\'s rank correlation analysis showed that leukocytic ROS generation in terms of MFI of DCF-DA and plasma levels of oxLDL were positively correlated with post-operative time after LVAD implantation (ρ = 0.861 , p \< 0.05 and ρ = 0.9783, p \<0.0001 respectively) whereas there was negative correlation between concentrations of SOD in erythrocytes and post-operative periods (ρ = - 0.7821, p \<0.001).

DNA damage and repair
---------------------

Changes in DNA damage and repair proteins in blood lymphocytes of the healthy control subjects and the HF patients before and after LVAD implantation is presented in Table [3](#T3){ref-type="table"}. To detect DNA double strand break in blood lymphocytes; γ-H2AX foci count was evaluated as each focus within nuclei represents single double strand break. Figure [3](#F3){ref-type="fig"} indicates the number of foci in nuclei of blood lymphocytes. The γ-H2AX foci count increased progressively in post-LVAD patients when compared to pre-LVAD patients and healthy controls. The HF patients have already 2.5-fold higher DNA damage than the healthy subjects. The mean number of γ-H2AX foci per nuclei increased by 8.4% (6.30 ± 2.42 vs 5.81 ± 2.19 in Pre-OP, p = 0.6776) in blood lymphocytes of the HF patients at POD-1W after LVAD implantation. However successive follow-up study up to 3 months shows that, the mean foci count increased by 2.5 fold (p = 0.0007) to 2.7 fold (p = 0.0008) at POD-2M and POD-3M compared to that that of the HF patients before LVAD implantation (Table [3](#T3){ref-type="table"}).

Increased Mre-11 foci count in nuclei of blood lymphocytes indicates accelerated DNA repair either via homologous recombination (HR) or non-homologous end joining (NHEJ) pathways (Figure [4](#F4){ref-type="fig"}, Table [3](#T3){ref-type="table"}). The mean γ-H2AX foci numbers positively correlated with the post-operative time after LVAD implantation (Spearman\'s *ρ*= 0.4835, p \< 0.01). Other proteins (DNA ligase IV, Ku70 and Ku80) that help to repair double strand break exclusively via NHEJ pathway was also higher as the percent positive nuclei of blood lymphocytes significantly increased in pre-operative blood of the HF patients than the healthy control subjects. Moreover these proteins expression became highest at POD-1W after LVAD implantation and then decreased thereafter (Table [3](#T3){ref-type="table"}).

Results are expressed as mean ± standard deviation (SD). For each subject, an average of 200 cells was screened to detect the protein expression. p\<0.05 is considered significant in Student\'s t-test. ^a^, p \< 0.05 compared with control, ^b^, p \< 0.05 compared with Pre-PO and ^c^, p \<0.05 compared with POD-1W

Relationship between oxidative stress and DNA damage repair
-----------------------------------------------------------

To establish a relationship between biomarkers of oxidative stress and DNA damage repair, we conducted Spearman\'s rank correlation test among LVAD recipients. Our study clearly indicated that γ-H2AX, Mre-11 and DNA ligase IV correlated positively with generation of ROS in leukocytes, in terms of MFI of DCF-DA, levels of oxLDL and negatively with concentration of SOD in erythrocytes (Table [4](#T4){ref-type="table"}). The correlation between biomarkers of oxidative stress and Ku70/Ku80 was not as strong as like other damage repair biomarkers.

Discussion
==========

Little is known about the role of continuous flow LVADs on oxidative stress and DNA damage repair among HF patients. To our knowledge, this is the first study to report on the status of oxidative stress, DNA damage and repair in end-stage heart failure patients supported by contentious-flow left ventricular assist devices. There are many experimental evidences from *in vitro* and animal studies that oxidative stress is common observable fact in heart failure condition [@B29]. Moreover, in animal models, the development of HF is accompanied by changes in the antioxidant defense mechanisms of the myocardium as well as elevated oxidative myocardial injury. We noticed excess ROS genetation from blood leukocytes and concomitant depletion of SOD activity in blood erythrocytes, elevated plasma levels of oxLDL, excess DNA double strand breaks and higher DNA repair proteins expression in blood lymphocytes of HF patients before LVAD implantation when compared to healthy controls. These findings suggest that oxidative stress and DNA damage in leukocytes are pre-existing conditions in HF patients. Although, we could not find any significant effects of drugs like warfarin, aspirin, digoxin carvedilol, atorvastatin and lisinopril on oxidative stress and DNA damage in pre-operative HF patients.

The causes of HF vary with age and family history. In our study, most of the HF patients are older people aged between 57 - 69 years with several other health related complications. Oxidative stress has been reported to increase in elderly subjects (55 - 70 yrs. old); possibly arising from an uncontrolled production of free radicals by ageing mitochondria and decreased antioxidant defenses [@B30]. The alcohol intake and tobacco smoking habits were much more common in HF failure patients and the current study is not exception to these facts. Most of the HF patients were addicted to tobacco use in terms of smoking for a long period in their life history. They generally smoke 7 - 20 cigarettes a day for the last 10 to 30 years. An addiction to the consumption of alcoholic liquor was evident in 80% HF patient in our study. On the other hand, half of them have history of diabetes mellitus and 70% are hypertensive. Smoking may enhance DNA damage in lymphocytes [@B31] and oxidative stress [@B32] in healthy individuals not only through the production of reactive oxygen radicals in smoke but also through weakening of the antioxidant defense systems. Elevated levels of oxidative stress and DNA damages are also evident in individuals with diabetes mellitus [@B33],[@B34] and hypertension [@B35],[@B36]. The influence of these conditions to produce excess oxidative stress and DNA damage repair cannot be explained in HF patients because both control and HF groups of this study were matched (Table [1](#T1){ref-type="table"}). Oxidative stress and DNA damage in the HF patients either suffering from Ischemic or non-ischemic cardiomyopathy was found to be similar.

In this study we also investigate the status of oxidative stress and DNA damage repair in the same HF patients after implantation of continuous flow LVAD. Interestingly, after implantation, the severity of oxidative stress and DNA damage become more prominent. Spearman\'s rank correlation test established a positive association between the biomarkers of oxidative stress and DNA damage after LVAD implantation. Post-operative days after implantation positively associated with increased production of ROS in blood leukocytes, plasma oxLDL levels and negatively with SOD generation in erythrocyte. Thus indicating persistent oxidative stress in these patients. Excess DNA damage after LVAD implantation is documented in terms of increased number of γ-H2AX foci count in nuclei of blood lymphocytes. This indicates most serious forms of genetic damage because each focus within nucleus represents DNA double strand break. Since both strands of the DNA double helix are broken, chromosomal fragmentation, translocation, and deletions can easily occur in these cells making them more vulnerable to genomic instability [@B37]. Positive association with post-implantation days was also noticed in case of DNA damage parameter. This underscores the importance of DNA repair in maintaining cellular homeostasis.

Double strand breaks (DNA damage) can be repaired either by homologous recombination (HR) or by non-homologous end joining (NHEJ) pathways. The first response of eukaryotic cells to DNA damage is the extensive phosphorylation of a member of histone H2A family like H2AX by ATM (Ataxia telangiectasia mutated) kinase. Phosphorylation occurs within 1-3 min after induction of DNA damage [@B38]. Rise in Mre11 foci count in nuclei of blood lymphocytes, as seen among LVAD recipients, is important in this context, because the MRN complex (Mre11, Rad50 and Nsb1) recruits ATM to the site of DNA damage where it first activates itself via autophosphorylation on Ser1981 and then phosphorylates many of its substrates including histone H2AX for initiation of DNA repair and cell cycle delay in case of cycling cells [@B39]. In our study, the magnitude of γ-H2AX and Mre11 foci formation in blood lymphocytes were correlated positively (Spearman\'s *ρ* = 0.9984, p\<0.0001) during the three month follow-up study after LVAD implantation, indicating an important step in the mobilization of the DNA repair machinery at the site of DNA damage.

The human Mre11 coordinates double strand break signaling with repair by homologous recombination and is associated with the H2AX chromatin response to damage [@B40]. Moreover, the role of Mre11 is also implicated in non-homologous end joining (NHEJ) - a double strand break repair mechanism prevalent in non-dividing cells [@B41]. Since we used blood lymphocytes that are in G0 phase of cell cycle, the higher Mre11 expression can\'t be explained by HR pathway, rather it can help to repair DNA damage partially through DNA broken end processing via NHEJ pathway.

We also study NHEJ pathway by examining the expression of DNA ligase IV, Ku70 and Ku80 in blood lymphocyte of the HF patients before and after LVAD implantation. To repair double strand breaks via NHEJ pathway, Ku70 forms a heterodimer with Ku80 and first binds to the broken ends of the damaged DNA [@B42] and then DNA ligase IV ligates the DNA end to complete the repair [@B42],[@B43]. Our results showed that these proteins were higher in nuclei of blood lymphocytes of the HF patients than the healthy controls even before LVAD implantation. Interestingly, after one week of LVAD implantation, these proteins became the highest and subsequently decreased at each month postoperatively but remained higher than the pre-operative values. These findings also tempts us to suggest that the HF patients supported by LVADs has higher levels of DNA damage in lymphocytes and subsequent activation of DNA repair pathway probably via NHEJ in which the HR protein Mre11 may plays an important role. The decreased NHEJ repair proteins after three month of LVAD implantation and the highest DNA double strand breaks at that time may pose a threat to genomic stability through damage accumulation within circulating leukocytes.

The HF patients undergoing LVAD implantation had a median body weight of 80 kilogram and after LVAD implantation we noticed significant loss of body weight especially in obese patients. Our finding is in general agreement with other reports that also showed reduction in total body weight after LVAD implantation [@B44],[@B45]. Weight loss is associated with increased oxidative DNA damage not only in healthy individuals but also in people with inflammatory diseases [@B46]. Moreover, Mizoue et al., 2007 established a statistically significant inverse relationship between body mass index (BMI) and marker of oxidative DNA damage among healthy indivuals [@B47]. So, the persistent oxidative stress and DNA damage may be partly related to the decreased body weight after transplantation although the role of continuous flow LVAD cannot be underestimated.

One potential limitation of continuous-flow pump technology is the relatively high nonphysiological shear stress imparted on blood components as they move through the device [@B48]. Using computational fluid dynamics study we recently showed that continuous flow LVAD generates high shear stresses especially from axial VADs compared to centrifugal VADs [@B49]. Generation of reactive oxygen species and DNA damage is also related to high shear stress [@B25],[@B26]. Thus long-term LVAD support may have an additive role in the excess production of ROS form circulating leukocytes and concomitant DNA damage in lymphocytes.

Complications during LVAD support, such as thromboembolism, bleeding, infections, and right ventricular failure remained an issue for long-term LVAD use. While staying in the intensive care units (ICUs) after LVAD implantation, patients encountered several clinical complications. Cardiogenic shock, pulmonary insufficiency following trauma or surgery, abnormal coagulation profile, anemia due to acute blood loss, thrombocytopenia, driveline infections, acute respiratory failure, acute renal failure, dysphagia and hyperglycemia were common during first two week of ICU stay. Non-surgical gastrointestinal bleeding events and right ventricular failure were noticed in 30% HF patients within one month of LVAD implantation. *Pseudomonas* infection was found in only two HF patients after implantation. This study indicated another important challenge of oxidative stress and concomitant DNA damage and repair after LVAD implantation in long-term basis. Besides genetic damage [@B28], long-term oxidative stress may be directly or indirectly related to several consequences like inflammations [@B50],[@B51], bacterial infections [@B52], respiratory disease [@B53], gastrointestinal bleeding [@B54] and even may promote the development of multiple organ failure [@B19].Thus continued improvement of LVAD technology for less traumatic devices and understanding of device-induced ROS and DNA damage continue to be important.

Study limitation
----------------

We acknowledge that our study has some limitations. This study was conducted in a single center, and consequently included a limited number of end-stage HF patients undergoing continuous flow LVAD implantation. Pre-implant HF patients were compared with matched healthy controls rather than comparative group of control patients with advanced HF, say INTERMACS 1,2 and 3. We also could not explore and show any causal relationship between LVAD parameter and ROS mediated DNA damage in HF patients after implantation. Hence, it is premature to comment on a possible direct causal relationship between LVAD parameters and subsequent ROS generation and DNA damage repair. Moreover we could not study the effects of medications used during the LVAD support although we mentioned the documentation medications on admission before LVAD implantation. Our current study has only 20% HF patients who were not addicted to alcoholic liquor consumption. So the relevance to more general (non-alcoholic) heart failure population is limited. Despite all these limitations, our study clearly indicated persistent oxidative stress, DNA damage and altered DNA repair in circulating blood cells after LVAD support. Further detailed investigations are necessary to find out the exact cause of oxidative stress and DNA damage repair in LVAD implanted HF patients.
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![Histograms showing levels of ROS generation (in terms of MFI of DCF-DA) in peripheral blood leukocytes \[neutrophils (A), lymphocytes (B) and monocytes (C)\], levels of SOD in erythrocytes (D) and levels of oxLDL in plasma (E) in control individuals, pre-operative (Pre-OP) and post-operative (POD-1W, POD-1M, POD-2M, POD-3M) heart failure patients. Bars represent standard deviation of mean. ^\*^, p\<0.05 compared with control in unpaired student\'s *t*-test, One way ANOVA for multiple comparison between Pre- and different Post-operative times found to be very significant (indicated as straight line with p values). ^†^, p\<0.05 compared with Pre-PO and ^‡^, p\<0.05 compared with POD-1W after post hoc range tests and multiple comparisons using Bonferroni corrections.](ijmsv10p0883g01){#F1}

![Photomicrograph showing ROS generation in the cytoplasm of blood neutrophils, lymphocytes and monocytes using wide-field fluorescence microscope equipped with standard green filter (490/525 nm). Note that the intensity of green fluorescence increases with increasing post-operative duration (POD-1W\< POD-1M \< POD-2M \< POD-3M) than pre-operative condition. The fluorescence intensity remains minimum in healthy control subjects. Magnification × 1,000.](ijmsv10p0883g02){#F2}

![Immunofluorescence microscopy showing γ-H2AX foci formation (green) in nuclei of blood lymphocytes of control, pre-operative and post-operative samples. Note highest number of γ-H2AX foci in nuclei of LVAD recipients after three month of implantation (POD-3M). Magnification × 1,000.](ijmsv10p0883g03){#F3}

![Immunofluorescence microscopy showing Mre-11 foci formation (red) in nuclei of blood lymphocytes of control, pre-operative and post-operative samples. Note highest number of foci in nuclei of LVAD recipients after three month of implantation (POD-3M). Magnification × 1,000.](ijmsv10p0883g04){#F4}

###### 

Demographic and Clinical Characteristics.

  Characteristics                                                Heart failure Patients (n=10)   Healthy Control subjects (n=10)
  -------------------------------------------------------------- ------------------------------- ---------------------------------
  **Demography**                                                                                 
  Age in years, median (range)                                   65 (57 - 69)                    63 (26 - 74)
  Sex (% male)                                                   80.00%                          80.00%
  Height in meter, median (range)                                1.72 (1.63 - 1.84)              1.68 (1.58 - 1.73)
  Weight in kilograms, median (range)                            79.80 (48.12 - 122.30)          76.83 (54.93 - 101.80)
  Body mass index (kg/m^2^), median (range)                      24.50 (17.00 - 36.40)           26.71 (20.80 - 27.09)
  Body surface area (m^2^), median (range)                       1.95 (1.50 - 2.49)              1.73 (1.66 - 1.93)
  History of tobacco smoking (%)                                 70.00 %                         70.00%
  History of alcohol intake (%)                                  80.00%                          80.00%
  **Past medical history**                                                                       
  Heart failure (%)                                              100 %                           0%
  Diabetes mellitus (%)                                          50 %                            50%
  Hypertension (%)                                               70 %                            70%
  **Etiology of heart disease**                                                                  
  Ischemic cardiomyopathy (%)                                    50 %                            0%
  Non-ischemic cardiomyopathy (%)                                50 %                            0%
  **Medications on admission**                                                                   
  Anticoagulants                                                                                 
  Warfarin (1.0 - 7.5 mg daily)                                  50%                             \-
  Non-steroid anti-inflammatory drug                                                             
  Aspirin (81 mg daily)                                          40%                             \-
  β-blockers (nonselective)                                                                      
  Carvedilol (3.125 - 12.5 mg daily)                             70%                             \-
  ACE inhibitor                                                                                  
  Lisinopril (5 - 40 mg daily)                                   30%                             \-
  Statins:HMG-CoA reductase inhibitors                                                           
  Atorvastatin (10 - 40 mg daily)                                50%                             \-
  Cardiac glycoside                                                                              
  Digoxin (125 µg daily)                                         40%                             \-
  **Echocardiographic parameters**                                                               
  Left ventricular end diastolic diameter (mm), median (range)   68 (48 - 77)                    \-
  Left ventricular ejection fraction, (%), median (range)        15 (10 - 20)                    \-
  **Types of LVAD**                                                                              
  HeartMate II (%)                                               50 %                            0%
  Jarvik 2000 (%)                                                50 %                            0%

###### 

Laboratory Hematology and blood chemistry.

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                   Healthy\      Normal range   Heart failure patients                                                      
                             Control                                                                                                  
  -------------------------- ------------- -------------- ------------------------ --------------- --------------- ------------------ -------------------
  Leukocytes (×10^3^/µL)     6.81±1.07     4.5-11.0       8.53±3.43                11.17±2.99      11.40±1.11^b^   10.25±1.29         8.70±2.57

  Erythrocytes (×10^6^/µL)   5.69±0.83     4.0-5.7        4.01±1.02^a^             3.04±0.33^b^    3.08±0.29^b^    3.21±1.07          3.14±0.88

  Platelet (×10^3^/µL)       227±52.03     153-367        175.50±75.74^a^          130±95.05       216±87.55       196.25±43.55       241.50±33.33^b,c^

  Hemoglobin (g/dL)          15.60±0.73    12.6-17.4      11.26±2.79^a^            8.97±0.88^b^    8.90±0.87^b^    9.38±2.90          9.28±2.32

  Hematocrit (%)             45.8±2.19     37-50          34.75±8.42^a^            26.81±2.55^b^   28.00±2.71^b^   30.60±9.28         28.90±7.80

  BUN (mg/dL)                14.76±4.57    9-20           30.50±11.47^a^           29.57±21.01     49.00±21.99     37.50±24.97        31.50±17.33

  Creatinine (mg/dL)         0.84±0.31     0.66-1.25      1.46±0.52^a^             1.59±1.25       2.01±1.85       1.14±0.65          1.47±1.01

  Total bilirubin (mg/dL)    0.34±0.11     0.2-1.3        2.71±1.44^a^             2.78±1.93       1.39±0.79^b^    0.77±0.30^b,c^     1.10±0.52^b,c^

  Direct bilirubin (mg/dL)   0.23±0.10     ≤0.4           1.50±0.62^a^             1.52±1.28       1.00±0.78       0.30±0.14^b,c^     0.35±0.07^b,c^

  AST (U/L)                  31.24±8.72    17-59          50.33±15.20^a^           49.5±17.73      50.14±19.55     31.75±11.47^b,c^   29.00±8.60^b,c^

  ALT (U/L)                  27.92±13.09   21-72          48.50±14.15^a^           34.71±22.12     54.71±31.79     23.50±7.85^b^      28.50±15.35^b^
  -------------------------------------------------------------------------------------------------------------------------------------------------------

BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase. Results are expressed as mean ± standard deviation and p\<0.05 is considered significant in Student\'s t-test. ^a^ p \< 0.05 compared with control, ^b^ p \< 0.05 compared with Pre-PO, ^c^p \<0.05 compared with POD-1W

###### 

Changes in DNA damage and repair proteins in blood lymphocytes.

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Biomarkers of DNA damage /repair   Healthy\      Heart failure patients                                                             
                                     Control                                                                                          
  ---------------------------------- ------------- ------------------------ ----------------- ------------------- ------------------- -------------------
  γ-H2AX foci per nucleus            2.32 ± 1.02   5.81 ± 2.19^a^           6.30 ± 2.42       9.83 ± 3.61^b,c^    14.72 ± 5.38^b,c^   15.92 ± 6.32^b,c^

  Mre-11 foci per nucleus            1.38 ± 0.56   3.57 ± 1.64^a^           4.22 ± 1.31       6.98 ± 1.02^b,c^    8.82 ± 2.11^b,c^    11.67 ± 3.58^b,c^

  DNA ligase V (% positive nuclei)   1.77 ± 0.23   3.89 ± 1.61^a^           19.88 ± 3.62^b^   12.32 ± 5.29^b,c^   7.11 ± 3.02^c^      8.22 ± 3.59^c^

  Ku70 (% positive nuclei)           2.11 ± 0.58   5.55 ± 3.02^a^           14.98 ± 6.29^b^   9.76 ± 3.33         8.82 ± 4.11         6.87 ± 3.11^c^

  Ku80 (% positive nuclei)           1.98 ± 0.43   7.88 ± 3.11^a^           18.83 ± 5.01^b^   11.08 ± 4.77^c^     9.91 ± 5.10^c^      7.71 ± 3.81^c^
  -------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Spearman correlation between biomarkers of oxidative stress and biomarkers of DNA damage repair in LVAD recipients.

  Biomarkers of oxidative stress   Biomarkers of DNA damage/repair                                                                                                   
  -------------------------------- --------------------------------- -------------- --------- -------------- --------- ------------ --------- ------------ --------- --------
  ROS                              0.9429                            \<0.0001^\*^   0.9427    \<0.0001^\*^   0.6145    0.0085^\*^   0.4857    0.0451^\*^   0.2571    0.3030
  oxLDL                            0.9753                            \<0.0001^\*^   0.9584    \<0.0001^\*^   0.4857    0.0410^\*^   0.4454    0.0760       0.2354    0.4285
  SOD                              -0.9924                           \<0.0001^\*^   -0.9245   \<0.0001^\*^   -0.4845   0.0421^\*^   -0.4286   0.0745       -0.2125   0.4262

Result was expressed as ρ (rho) value.^\*^, statistically significant in spearman\'s rank correlation test.
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